Presentation is loading. Please wait.

Presentation is loading. Please wait.

Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Photo: Jarle Bruun.

Published byDillon Fason Modified over 9 years ago

Similar presentations

Presentation on theme: "Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Photo: Jarle Bruun."— Presentation transcript:

1 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Photo: Jarle Bruun Guro E. Lind Department of Cancer Prevention Ragnhild A. Lothe group Cancer Biomedicine University of Oslo Biomarkers for non-invasive testing for colorectal cancer Photo: Jarle Bruun ”Life sciences for health and innovation” Oct 11th 2011, Oslo

2 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Early diagnosis will improve patient survival Illustration is modified from National Cancer Institute

3 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Early diagnosis will improve patient survival Illustration is modified from National Cancer Institute 90% 81% 63% 9% Survivial: data from the Norwegian Cancer Registry, 2009 SURVIVAL 5 years

4 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine ”Window of opportunity” for diagnostics Normal mucosa Carcinoma Intermed. adenoma Small adenoma Large adenoma Diagnostics 5-35 years

5 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine FOBT = fecal occult blood test Well established, simple, reduce mortality of CRC Unspecific, limited sensitivity, and limited detection of precursors (adenomas) Blood/plasma/serum test -Epi ProColon test. Methylation marker, SEPT9. Fecal DNA test Limited sensitivity and specificity -The ColoSure test. Methylation marker, VIM Need for additional tests/biomarkers

6 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Project progress and time frame Experimental pipeline Results New strategy for identification of methylated candidates Lind et al Cell. Oncol. 2006 Proof-of-principle Lind et al Gastroenterology 2007 Clinical validation of first biomarker Lind et al J Transl Med. 2008 Methylation in precursor lesions Ahlquist et al Mol Cancer. 2008 Panel of biomarkers published Lind et al Mol Cancer. 2011 Analysis of biological function Lind et al Oncogene. 2011 Innovation/development DOFI signed, patent application 2007 PCT/EP2008 PA published, WO 2008/102002 2008 R&D, TTO Biotech conferences 2009 MTA phase I-II signed Eur Biotech comp 2010 License agreement? 2011 Six biomarkers identified

7 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Clinical test and validation series Normal mucosa Carcinoma Intermed. adenoma Small adenoma Large adenoma N = 61 NormalBenign N = 51 Malignant N = 80 Test N = 59N = 105N = 52 Validation

8 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Biomarker performance Sensitivity Adenoma (n=111) Carcinoma (n=179) Spesificity Normal mucosa n=110 93% 94% 98%

9 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine ROC confirms high sensitivity and specificty

10 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine ”Clinical proof of concept”: Non-invasive testing using fecal samples Malignant N = 72 Carcinomas Fecal samples Blood samples Benign N = 30 Adenomas Fecal samples Blood samples N = 30 Normal mucosa Fecal samples Blood samples Normal NordICC screening

11 Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Collaborators Cancer Registry Dr. Michael Bretthauer Prof. Geir Hoff Oslo University Hospital Prof Arild Nesbakken Dr. Espen Thiis-Evensen Prof. Torleiv O. Rognum Department of Cancer Prevention Prof. Ragnhild A. Lothe Group leader and head of Department Stine A. Danielsen Hilde Honne www.rr-research.no/cancerprevention

Download ppt "Oslo University Hospital Department of Cancer Prevention Institute for Cancer Research Radiumhospitalet Centre for Cancer Biomedicine Photo: Jarle Bruun."

Similar presentations

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.

Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM April 3, 2014 Vol 3 Imperiale, T.F. et al Presented by Melissa Spera, MD.

Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM April 3, 2014 Vol 3 Imperiale, T.F. et al Presented by Melissa Spera, MD.
The Wall Street Analyst Forum’s 17 th Annual Analyst Conference.

The Wall Street Analyst Forum’s 17 th Annual Analyst Conference.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Joint Hospital Surgical Grand Round 19 June 2004.

Joint Hospital Surgical Grand Round 19 June 2004.
Update on Colorectal Cancer Screening Tests Source: Levin Bernard et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous.

Update on Colorectal Cancer Screening Tests Source: Levin Bernard et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous.
Tryggvi Björn Stefánsson Dept of Surgery Landspitali University Hospital.

Tryggvi Björn Stefánsson Dept of Surgery Landspitali University Hospital.
Experimental Design and Biospecimens David F. Ransohoff, MD Division of Gastroenterology and Hepatology; Dept. of Medicine.

Experimental Design and Biospecimens David F. Ransohoff, MD Division of Gastroenterology and Hepatology; Dept. of Medicine.
Stage-specific survival of screen-detected versus clinically diagnosed colorectal cancer - evidence from the FOBT screening trials- Iris Lansdorp-Vogelaar.

Stage-specific survival of screen-detected versus clinically diagnosed colorectal cancer - evidence from the FOBT screening trials- Iris Lansdorp-Vogelaar.
Eleni Galani Medical Oncologist

Eleni Galani Medical Oncologist
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.

Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Colorectal Screening NZ Bowel Screening Pilot. WHO Screening criteria  Impt Health condition  Identifiable Latent or early stage  Understand natural.

Colorectal Screening NZ Bowel Screening Pilot. WHO Screening criteria  Impt Health condition  Identifiable Latent or early stage  Understand natural.
Development of Plasmid Calibrators for Absolute Quantification of MicroRNAs by Real Time Quantitative PCR: A new tool for personalized medicine N. Beaufils.

Development of Plasmid Calibrators for Absolute Quantification of MicroRNAs by Real Time Quantitative PCR: A new tool for personalized medicine N. Beaufils.
Emerging Issues in Cancer Control: The Perspective from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Martin D. Abeloff, M.D. Director.

Emerging Issues in Cancer Control: The Perspective from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Martin D. Abeloff, M.D. Director.
Cytologic and DNA- Cytometric Early Diagnosis of Oral Cancer Torsten W. Remmerbach, Horst Weidenbach, Natalja Pomjanski, Kristiane Knops, Stefanie Mathes,

Cytologic and DNA- Cytometric Early Diagnosis of Oral Cancer Torsten W. Remmerbach, Horst Weidenbach, Natalja Pomjanski, Kristiane Knops, Stefanie Mathes,
Organized Diagnostic Assessment Demonstration Projects Organized Diagnostic Assessment Demonstration Projects Streamlined Centre for Out-Patient Endoscopy.

Organized Diagnostic Assessment Demonstration Projects Organized Diagnostic Assessment Demonstration Projects Streamlined Centre for Out-Patient Endoscopy.
Chair of Oncology, Semmelweis University, Budapest National Institute of Oncology, 1122 Ráth Gy. u. 7-9. Head: Prof. Csaba Polgár –Phone: +36-1-224-8690.

Chair of Oncology, Semmelweis University, Budapest National Institute of Oncology, 1122 Ráth Gy. u Head: Prof. Csaba Polgár –Phone:
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.

Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.

Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.

Similar presentations

Ads by Google